Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients With Type 2 Diabetes
Phase of Trial: Phase IV
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EMPA-HEART
- 31 Jan 2017 Status changed from not yet recruiting to recruiting.
- 05 Jan 2017 Planned initiation date changed from 1 Dec 2016 to 1 Jan 2017.
- 23 Dec 2016 New trial record